Marinus Pharmaceuticals Inc logo

Marinus Pharmaceuticals Inc

$ 6.65 -0.37 (-5.27%) 04:00 PM EST
P/E:
At Loss
P/B:
332.04
Market Cap:
$ 246.67M
Enterprise V:
$ 245.47M
Volume:
493.21K
Avg Vol (2M):
218.91K
Also Trade In:
Volume:
493.21K
Market Cap $:
246.67M
PE Ratio:
At Loss
Avg Vol (2-Month):
218.91K
Enterprise Value $:
245.47M
PB Ratio:
332.04
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
Name Current Vs Industry Vs History
Cash-To-Debt 1.27
Equity-to-Asset 0.04
Debt-to-Equity 15.12
Debt-to-EBITDA -0.73
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -6.42
Distress
Grey
Safe
Beneish M-Score -1.31
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 61.06
9-Day RSI 57.59
14-Day RSI 56.68
6-1 Month Momentum % -32.97
12-1 Month Momentum % -41.37

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.37
Quick Ratio 4.37
Cash Ratio 4
Days Sales Outstanding 39.11
Days Payable 745.81

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -41
Name Current Vs Industry Vs History
Gross Margin % 94.65
Operating Margin % -361.33
Net Margin % -386.11
ROE % -195.79
ROA % -79.45
ROIC % -669.63
ROC (Joel Greenblatt) % -3189.03
ROCE % -93.78

Financials (Next Earnings Date:2022-11-09 Est.)

MRNS's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:MRNS

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 27.61
EPS (TTM) ($) -2.88
Beta 0.6
Volatility % 62.25
14-Day RSI 56.68
14-Day ATR ($) 0.509443
20-Day SMA ($) 6.71025
12-1 Month Momentum % -41.37
52-Week Range ($) 3.97 - 13.15
Shares Outstanding (Mil) 37.2

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Marinus Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Marinus Pharmaceuticals Inc Analysis

Share your research

Headlines

See More
No news.